Company intelligence / Profile preview
Calviri
Phoenix, Arizona, United Statescalviri.com ↗
- Ownership
- Private
- Employees
- ~17
- Development stage
- Phase 2
01
Overview
Calviri has developed a novel cancer vaccine based on tumor-specific neoantigens from RNA errors. Its canine preventative cancer vaccine is in advanced clinical trials and has shown promise in preventing eight types of canine cancers. Human therapeutic vaccines are at the preclinical stage. The company also offers early-stage multi-cancer diagnostic tests using its proprietary peptide array technology[3][4][5].
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Therapeutic vaccinesPeptide arrays (for diagnostics)Monoclonal antibodies (patents)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Arizona State University Biodesign Institute / Skysong Innovations—licensing and research collaboration partner for core technology[4].
Beyond the preview
Go deeper on Calviri.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calviri.